Table 3.
UDT Results for Patient and Opioid Subgroups
| Variable | All UDTs N = 5,420 UDTs %* |
Any aberrant result n = 1,647/5,387 UDTs %† |
Prescribed opioid non-detection n = 656/5,334 UDTs %† |
THC, no illicit drug n = 565/5,162 UDTs %† |
Non-pre-scribed opioid n = 283/5,377 UDTs %† |
Illicit drug n = 29/5,162 UDTs %† |
Non-prescribed benzodiazepine n = 90/5,162 UDTs %† |
Dilute n = 258/5,420 UDTs %† |
|---|---|---|---|---|---|---|---|---|
| Gender | ||||||||
| Female | 59.7 | 29.0 | 12.1 | 7.9 | 5.2 | 0.6 | 1.7 | 6.2 |
| Male | 40.3 | 32.9 | 12.7 | 15.3 | 5.4 | 0.5 | 1.8 | 2.7 |
| Age, years | ||||||||
| 20–44 | 13.8 | 41.8 | 18.4 | 18.0 | 9.3 | 1.4 | 1.7 | 4.9 |
| 45–64 | 58.6 | 33.4 | 13.1 | 13.2 | 5.0 | 0.4 | 2.1 | 4.8 |
| 65+ | 27.5 | 18.9 | 7.4 | 2.6 | 3.9 | 0.4 | 1.1 | 4.7 |
| Race | ||||||||
| White | 84.6 | 29.5 | 11.4 | 10.3 | 4.8 | 0.5 | 1.8 | 5.1 |
| African-American | 4.0 | 34.4 | 15.0 | 16.0 | 9.4 | 0.9 | 0.5 | 0.9 |
| Other | 7.7 | 37.3 | 19.1 | 11.6 | 6.6 | 1.5 | 1.3 | 4.6 |
| Missing | 3.8 | 37.9 | 15.6 | 17.3 | 8.7 | 0 | 2.5 | 1.9 |
| Ethnicity | ||||||||
| Non-Hispanic | 92.3 | 30.2 | 12.1 | 10.5 | 5.2 | 0.6 | 1.7 | 4.9 |
| Hispanic | 3.7 | 33.2 | 12.2 | 13.2 | 5.0 | 0 | 2.5 | 2.5 |
| Missing | 3.9 | 38.0 | 17.1 | 18.8 | 7.1 | 0 | 2.4 | 2.8 |
| Mental health diagnosis | ||||||||
| No | 44.7 | 29.2 | 11.5 | 10.7 | 5.1 | 0.6 | 1.2 | 4.5 |
| Yes | 55.3 | 31.7 | 12.9 | 11.1 | 5.4 | 0.5 | 2.2 | 5.0 |
| Alcohol use disorder diagnosis | ||||||||
| No | 93.3 | 30.5 | 12.1 | 10.9 | 5.4 | 0.5 | 1.7 | 4.9 |
| Yes | 6.7 | 31.1 | 14.5 | 12.2 | 3.9 | 0.9 | 2.3 | 3.3 |
| Substance use disorder diagnosis | ||||||||
| No | 86.6 | 29.6 | 11.9 | 10.1 | 5.1 | 0.5 | 1.6 | 4.8 |
| Yes | 13.5 | 37.0 | 14.8 | 16.7 | 6.6 | 1.3 | 2.4 | 4.5 |
| Current smoker | ||||||||
| No | 69.9 | 27.0 | 11.4 | 8.2 | 5.1 | 0.4 | 1.5 | 4.3 |
| Yes | 30.1 | 38.8 | 14.4 | 17.5 | 5.6 | 0.9 | 2.2 | 6.0 |
| Opioid daily MED | ||||||||
| <40 mg | 59.9 | 33.5 | 17.0 | 11.0 | 4.9 | 0.7 | 1.4 | 4.5 |
| 40–< 120 mg | 28.6 | 26.1 | 6.6 | 11.0 | 5.3 | 0.5 | 2.0 | 4.6 |
| 120+ mg | 11.5 | 26.7 | 2.3 | 10.3 | 7.1 | 0.3 | 3.1 | 6.4 |
| Days’ supply | ||||||||
| Less than daily | 20.4 | 32.1 | 16.0 | 12.3 | 3.7 | 0.4 | 1.6 | 3.4 |
| Daily/near-daily | 52.3 | 30.4 | 12.3 | 10.3 | 5.4 | 0.6 | 1.7 | 5.0 |
| Excessive | 27.3 | 29.8 | 9.6 | 11.2 | 6.1 | 0.6 | 1.9 | 5.2 |
| Opioid type | ||||||||
| Short-acting only | 63.3 | 34.1 | 17.2 | 11.2 | 5.2 | 0.6 | 1.5 | 4.7 |
| Long-acting only | 9.9 | 24.9 | 4.2 | 10.2 | 5.6 | 0.4 | 2.2 | 5.0 |
| Long-acting plus short-acting | 26.9 | 24.5 | 4.1 | 10.7 | 5.3 | 0.5 | 2.1 | 4.7 |
UDT urine drug test, THC tetrahydrocannabinol, MED morphine-equivalent dose
* Percentage of all 5,420 UDTs. For example, among the 5,420 UDTs, 59.7 % were for females.
† Percentages are based on UDTs for each subgroup. For example, among UDTs for females, 29 % had an aberrant result.